AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03965494

Recruitment Status : Terminated (NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer - official close date is 10/31/23)

First Posted : May 29, 2019

Last Update Posted : February 8, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

National Cancer Institute (NCI)

BerGenBio ASA

Information provided by (Responsible Party):

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	October 31, 2023
Actual Study Completion Date :	October 31, 2023

To Top